zika
flaviviru
infect
pregnanc
appear
produc
higher
risk
microcephali
also
caus
multipl
neurolog
problem
syndrom
zika
viru
widespread
central
south
america
anticip
becom
increas
risk
southern
unit
state
continu
global
travel
spread
mosquito
vector
exposur
expect
acceler
current
approv
treatment
zika
viru
zika
proteas
attract
drug
target
due
essenti
role
viral
replic
studi
identifi
sever
compound
inhibitori
activ
ic
bind
affin
k
zika
proteas
test
hcv
inhibitor
initi
discov
highthroughput
screen
compound
competit
surfac
plasmon
reson
studi
mechan
inhibit
analys
enzym
kinet
subsequ
determin
best
compound
competit
inhibitor
k
valu
also
determin
xray
structur
zika
proteas
preopen
conform
conform
never
observ
flaviviru
proteas
provid
foundat
new
structurebas
inhibitor
design
zika
flaviviru
serin
proteas
small
molecul
inhibitor
apo
zikv
pro
structur
lee
et
al
zika
flaviviru
zikv
close
relat
dengu
west
nile
yellow
fever
virus
kuno
et
al
infect
result
rel
mild
clinic
symptom
includ
mild
fever
rash
arthriti
headach
conjunct
edema
seldom
result
hospit
death
paixao
et
al
zikv
isol
zika
forest
uganda
dick
et
al
although
aed
aegypti
main
epidem
vector
viru
isol
multipl
aed
speci
probabl
also
involv
zikv
transmiss
human
paixao
et
al
initi
endem
africa
zikv
spread
explos
latin
america
case
also
report
europ
oceania
southeast
asia
throughout
america
dyer
gather
kohl
gulland
imperato
malon
et
al
paixao
et
al
infect
pregnanc
appear
produc
higher
risk
microcephali
mayor
mirandafilho
dde
et
al
paixao
et
al
vogel
weaver
et
al
zikv
target
neural
stem
cell
receptor
axl
nowakowski
et
al
recent
observ
also
suggest
zikv
infect
induc
syndrom
paixao
et
al
smith
mackenzi
wise
indic
zikv
highli
neurotrop
induc
multipl
neuron
effect
chan
et
al
nowakowski
et
al
although
zika
vaccin
urgent
need
develop
like
year
away
cohen
weaver
et
al
thu
altern
therapeut
need
prophylaxi
prevent
inhibit
infect
postinfect
therapi
malon
et
al
weaver
et
al
zika
small
envelop
posit
singlestrand
rna
viru
within
genu
flaviviru
famili
flavivirida
cunha
et
al
also
includ
close
relat
west
nile
dengu
virus
gould
solomon
although
evid
yet
highli
diverg
strain
current
latin
american
epidem
cunha
et
al
malon
et
al
like
zikv
subject
high
mutat
rate
due
lack
proof
read
function
rna
polymeras
domain
zikv
encod
singl
polyprotein
contain
three
structur
seven
nonstructur
protein
two
form
singl
essenti
viral
proteas
complex
serin
proteas
fig
fay
et
al
base
dengu
west
nile
preced
proteas
expect
cleav
five
site
releas
result
nonstructur
protein
sampath
padmanabhan
addit
proteas
implic
immun
evas
cleavag
human
mediat
activ
interferon
regulatori
factor
activ
regul
antivir
respons
trigger
dengu
infect
aguirr
et
al
thu
probabl
dual
function
target
whose
inhibit
inhibit
viral
replic
protect
innat
immun
contain
proteas
domain
nterminu
rna
helicas
domain
cterminu
proteas
domain
belong
trypsinchymotrypsin
proteas
superfamili
catalyt
triad
compris
residu
fig
c
erbel
et
al
requir
membranebound
protein
posit
catalyt
triad
substrat
although
overal
structur
zika
viru
publish
sirohi
et
al
yet
crystal
structur
fulllength
zika
protein
deposit
pdb
howev
structur
individu
proteas
helicas
domain
inhibitor
atp
respect
recent
publish
phoo
et
al
tian
et
al
ctermin
region
contribut
catalyt
pocket
shape
form
part
recognit
site
aleshin
et
al
erbel
et
al
hammami
et
al
robin
et
al
limit
research
develop
zika
therapeut
date
although
test
repurpos
hepat
c
viru
hcv
therapeut
propos
malon
et
al
closer
preced
develop
therapeut
dengu
viru
denv
west
nile
viru
wnv
target
nonstructur
protein
essenti
viral
replic
pursu
mani
research
group
includ
develop
inhibitor
proteas
helicas
domain
methyl
transferas
rna
polymeras
domain
bhakat
et
al
lim
et
al
although
promis
progress
particularli
dengu
research
still
earli
lead
phase
efficaci
still
far
behind
develop
therapeut
relat
hcv
proteas
particularli
promis
flaviviru
therapeut
target
extens
research
develop
inhibitor
therapeut
candid
variou
strategi
dengu
inhibitor
develop
recent
review
luo
et
al
includ
design
peptid
prusi
et
al
xu
et
al
nonpeptid
small
molecul
inhibitor
cabarcasmontalvo
et
al
chu
et
al
deng
et
al
lai
et
al
lai
et
al
li
et
al
liu
et
al
tomlinson
watowich
viswanathan
et
al
wu
et
al
zhou
et
al
alreadi
indic
resist
proteas
inhibitor
develop
readili
yang
et
al
yang
et
al
consist
hcv
proteas
inhibitor
experi
romano
et
al
high
error
rate
zika
polymeras
like
produc
divers
viral
variant
facilit
resist
develop
similar
hcv
proteas
inhibitor
experi
halfon
locarnini
thu
develop
zika
proteas
inhibitor
activ
potenti
drugresist
mutant
would
highli
desir
antivir
therapi
prophylaxi
report
multipl
inhibitor
identifi
repurpos
previous
identifi
hcv
inhibitor
lee
et
al
inhibitori
activ
direct
bind
compound
zika
pro
also
explor
follow
mechan
inhibit
studi
addit
attempt
determin
xray
structur
zika
pro
complex
inhibitor
identifi
apo
conform
pro
never
observ
flaviviru
proteas
new
protein
structur
preopen
confirm
repres
new
target
fold
pro
structurebas
inhibitor
design
gene
zikv
proteas
residu
histag
nterminu
residu
codonoptim
synthes
biobas
inc
clone
vector
ndei
bamhi
human
rhinoviru
hrv
proteas
cleavag
site
insert
right
one
liter
cell
contain
recombin
zika
pro
gene
grown
od
lb
medium
cell
induc
mm
iptg
hour
harvest
cell
lyse
sonic
lysi
buffer
mgml
lysozym
buffer
mm
tri
ph
mm
nacl
mm
imidazol
glycerol
mm
histag
fuse
zikv
pro
purifi
histrap
hp
column
ge
healthcar
stepwis
gradient
buffer
b
mm
tri
ph
mm
nacl
mm
imidazol
glycerol
mm
pool
zikv
pro
dialyz
buffer
without
imidazol
histag
cleav
unitsml
hrv
proteas
novagen
overnight
produc
zikv
pro
two
extra
residu
gp
nterminu
final
zikv
pro
load
onto
histrap
column
remov
hrv
proteas
cleav
histag
uncleav
histag
zikv
pro
purifi
protein
approxim
puriti
flash
frozen
liquid
nitrogen
storag
activ
histag
nativ
zikv
pro
enzym
measur
continu
kinet
assay
amc
substrat
bocglyargargamc
bachem
bioscienc
gener
fluoresc
signal
excit
nm
emiss
nm
aminomethylcoumarin
amc
cleav
zikv
pro
assay
perform
assay
buffer
contain
mm
tri
ph
chap
glycerol
mm
reduc
glutathion
gsh
seri
substrat
concentr
prepar
triplic
enzym
reaction
initi
ad
zikv
pro
enzym
nm
final
concentr
seri
substrat
concentr
without
enzym
also
measur
control
fluoresc
intens
continu
monitor
least
minut
polarstar
optima
micropl
reader
bmg
labtech
assay
perform
final
assay
volum
low
volum
black
micropl
corn
inc
michaelismenten
constant
k
maxim
activ
v
max
calcul
use
sigmaplot
fit
data
singl
rectangular
hyperbol
equat
also
known
michaelismenten
equat
initi
veloc
x
concentr
substrat
initi
inhibitor
test
mm
stock
solut
compound
life
chemic
synthes
prepar
dmso
zikv
pro
final
nm
distribut
plate
compound
ad
follow
min
incub
room
temperatur
enzym
reaction
initi
ad
substrat
final
fluoresc
intens
continu
monitor
least
min
polarstar
optima
micropl
reader
bmg
labtech
compound
test
triplic
ic
valu
measur
concentr
enzym
substrat
initi
screen
seri
compound
concentr
enzym
reaction
initi
ad
fluorogen
substrat
activ
continu
monitor
least
minut
ic
valu
calcul
fit
three
paramet
hill
equat
sigmaplot
percent
inhibit
x
inhibitor
concentr
n
slope
concentrationrespons
curv
hill
slope
v
max
maxim
inhibit
three
independ
assay
sensor
surfac
first
activ
carbodiimid
hydrochlorid
edc
nhydroxi
succinimid
nh
mixtur
purifi
zikv
pro
dilut
mm
sodium
acet
ph
concentr
immobil
flow
cell
pbsp
mm
phosphat
ph
mm
kcl
mm
nacl
run
buffer
use
biacor
instrument
ge
healthcar
standard
amin
coupl
unmodifi
surfac
flow
cell
use
control
analyz
compound
initi
prepar
mm
stock
dmso
solut
compound
solut
seri
increas
concentr
dilut
appli
four
channel
spr
bind
buffer
pbsp
mm
tcep
flow
rate
respons
unit
ru
valu
concentr
measur
equilibr
phase
steadyst
affin
fit
use
biacor
evalu
softwar
embed
equat
max
k
x
respons
max
maximum
respons
x
test
compound
concentr
data
referenc
blank
cell
ru
valu
enzym
activ
zikv
pro
investig
way
ic
valu
determin
vari
concentr
substrat
inhibitor
concentr
compound
vari
least
ic
valu
compound
data
fit
four
equat
use
sigmaplot
enzym
kinet
modul
order
determin
best
fit
inhibit
mechan
kinet
paramet
compound
lee
reaction
rate
v
max
maximum
rate
reaction
k
micha
protein
prepar
wizard
suit
use
optim
crystal
structur
zikv
complex
boron
inhibitor
pdb
code
sinc
crystallograph
dimer
singl
construct
chain
select
dock
restrain
minim
perform
hydrogen
rmsd
heavi
atom
converg
less
forc
field
structur
compound
creat
ligprep
forc
field
appli
ligand
geometr
optim
possibl
ioniz
tautomer
form
creat
ph
epik
shelley
et
al
default
valu
util
paramet
protein
ligand
prepar
molecular
dock
perform
use
gold
verdonk
et
al
prepar
protein
ligand
activ
site
zikv
defin
shell
residu
within
around
catalyt
residu
proteas
domain
protein
fix
dock
default
paramet
use
best
score
pose
compound
chosen
analysi
zika
pro
concentr
use
vivaspin
centrifug
concentr
ge
healthcar
life
scienc
mgml
sodium
chlorid
trishcl
ph
sit
drop
crystal
plate
set
room
temperatur
crystal
obtain
classic
ii
screen
qiagen
concentr
protein
plu
reservoir
condit
sodium
malon
wv
peg
harvest
crystal
transfer
reservoir
solut
rapidli
cool
liquid
nitrogen
diffract
data
collect
k
life
scienc
collabor
access
team
advanc
photon
sourc
argonn
illinoi
ap
beamlin
structur
work
perform
csgik
anderson
data
process
use
index
integr
scale
otwinowski
z
crystal
structur
zika
viru
proteas
complex
boron
inhibitor
pdb
code
use
molecular
replac
phase
structur
structur
refin
refmac
murshudov
et
al
model
display
coot
manual
correct
base
electron
densiti
map
emsley
cowtan
structur
figur
prepar
use
pymol
molecular
graphic
system
version
llc
structur
deposit
pdb
wwwwwpdborg
pdb
code
zikv
encod
singl
essenti
viral
proteas
complex
serin
proteas
singl
chain
pro
enzym
zikv
overexpress
ecoli
linker
consist
ggggsgggg
core
region
proteas
domain
fig
base
flaviviru
proteas
potenti
cleavag
site
zikv
within
nonstructur
protein
summar
fig
among
commerci
avail
substrat
flavivirus
use
bocgrramc
kinet
paramet
determin
assay
optim
test
compound
k
valu
zikv
pro
tabl
substrat
much
larger
report
k
valu
anoth
substrat
bznlekrramc
substrat
bocgrramc
contain
similar
residu
gkr
two
cleavag
site
bznlekrramc
contain
residu
krr
one
cleavag
site
fig
two
k
valu
indic
zikv
pro
enzym
higher
affin
bznlekrramc
bocgrramc
k
cat
valu
zikv
enzym
k
cat
k
valu
zikv
pro
zikv
pro
enzym
initi
overexpress
hexahistidin
tag
enzym
cleavag
site
yield
nativ
construct
possibl
cleav
tag
k
valu
tag
zikv
pro
larger
nativ
one
result
slightli
smaller
k
cat
k
valu
base
determin
k
valu
decid
use
substrat
test
potenti
inhibitor
import
factor
reduc
agent
deterg
dmso
toler
zika
enzym
investig
determin
optim
assay
condit
test
larg
number
compound
high
throughput
screen
compound
previous
identifi
hcv
inhibitor
ic
valu
genotyp
competit
respect
substrat
indic
direct
bind
proteas
activ
site
lee
et
al
inhibitor
also
select
multipl
hcv
genotyp
two
human
serin
proteas
trypsin
chymotrypsin
subsequ
identifi
hcv
proteas
inhibitor
low
activ
follow
overal
workflow
shown
fig
note
strong
structur
similar
catalyt
region
zikv
hcv
proteas
test
promis
hcv
inhibitor
identifi
compound
inhibitori
activ
ic
valu
less
fig
spr
analysi
direct
bind
measur
k
also
gener
consist
ic
inhibit
valu
valid
posit
hit
spr
sensorgram
steadyst
affin
fit
curv
compound
shown
fig
exampl
ic
valu
compound
compar
determin
k
ten
test
compound
six
exhibit
ic
k
valu
ten
compound
categor
two
differ
scaffold
nine
compound
belong
scaffold
compound
one
differ
scaffold
scaffold
contain
sulfonamid
benzothiazol
group
scaffold
sulfonamid
thiazol
connect
adjac
compound
ic
k
valu
seem
best
lead
studi
extens
studi
done
develop
inhibitor
hcv
dengu
proteas
two
main
categori
develop
inhibitor
catalyt
site
bind
inhibitor
alloster
inhibitor
alloster
inhibitorbind
site
locat
proteas
helicas
domain
hcv
zikv
proteas
inhibitor
report
date
peptidomimet
boronicacid
inhibitor
bind
catalyt
site
competit
inhibitor
respect
substrat
bznlelyslysargamc
inhibitori
activ
main
lead
compound
exhibit
ic
valu
respect
fig
mechan
inhibit
enzymat
test
vari
concentr
inhibitor
substrat
bocglyargargamc
dixon
analysi
show
compound
competit
inhibitor
zikv
k
valu
fig
compound
also
determin
competit
inhibitor
k
valu
orthogon
valid
result
competit
spr
analys
compound
perform
absenc
presenc
substrat
bind
affin
k
compound
presenc
substrat
weaker
compound
alon
fig
support
design
competit
inhibitor
compound
k
valu
reduc
factor
substrat
present
fig
strongli
confirm
competit
inhibitor
enzymat
studi
competit
spr
bind
analys
compound
competit
inhibitor
respect
substrat
indic
bind
within
substrat
bind
region
adjac
catalyt
site
zikv
dock
studi
done
visual
potenti
bind
pose
compound
catalyt
site
best
fit
dock
pose
shown
fig
two
main
contribut
interact
hbond
pipi
interact
dock
sulfonamid
compound
form
two
hbond
sidechain
oh
fig
backbon
nh
addit
phenyl
ring
middl
compound
form
pipi
stack
interact
benzothiazol
ring
form
pipi
stack
interact
crystal
structur
proteas
without
inhibitor
ligand
determin
space
group
r
factor
r
free
good
stereochemistri
tabl
pdb
contain
two
molecul
chain
b
asymmetr
unit
structur
typic
chymotrypsinlik
fold
observ
proteas
complex
boron
inhibitor
proteas
flavivirus
structur
made
two
form
six
catalyt
triad
locat
cleft
two
fig
erbel
et
al
apo
structur
report
structur
complex
boron
inhibitor
similar
rmsd
posit
fig
model
residu
span
sequenc
chain
chain
b
fig
residu
c
terminu
disord
consequ
includ
model
fig
resid
inhibitor
bound
structur
form
essenti
shape
catalyt
activ
site
close
conform
close
conform
observ
substratelik
inhibitor
cocrystal
flaviviru
proteas
suggest
cterminu
becom
order
upon
bind
substrat
substratelik
molecul
explain
cterminu
requir
catalyt
activ
vitro
compar
avail
structur
flaviviru
pro
instead
openlik
conform
conform
cterminu
away
activ
site
pro
apo
structur
report
addit
uniqu
conform
pro
cterminu
also
make
differ
previous
report
open
structur
inde
seen
open
conform
flaviviru
pro
ie
dengu
viru
pro
pdbcode
pro
shorter
form
fig
erbel
et
al
robin
et
al
structur
cterminu
pro
move
away
substrat
bind
site
make
instead
hydrophob
interact
strand
connect
two
pro
fig
structur
featur
describ
preopen
conform
never
observ
structur
flaviviru
proteas
miss
preopen
conform
alter
structur
pro
cterminu
coincid
somewhat
differ
orient
two
chain
crystallograph
dimer
respect
fig
describ
two
independ
subunit
may
repres
dimer
asymmetr
unit
substratebind
site
two
monom
face
buri
surfac
area
less
compar
howev
calcul
pdbepi
http
wwwebiacukpdbepisa
similar
kcalmol
apo
form
compar
kcalmol
suggest
possibl
dimer
might
form
independ
substrat
bind
substrat
access
bind
site
two
open
side
dimer
previous
suggest
structur
individu
subunit
may
connect
neighbor
molecul
crystal
lattic
disulfid
bond
link
monom
residu
b
symmetri
relat
molecul
howev
resolut
structur
allow
us
conclus
presenc
ss
bond
two
cystein
distanc
may
occur
molecul
crystal
lattic
although
multipl
proteas
inhibitor
approv
hepat
c
viru
hcv
other
propos
close
relat
dengu
west
nile
virus
inhibitor
design
proteas
still
challeng
activ
site
shallow
solvent
expos
flexibl
moreov
analog
hcv
proteas
inhibitor
resist
expect
aris
zika
proteas
inhibitor
studi
build
foundat
prior
work
identifi
inhibitor
activ
multipl
genotyp
common
resist
mutat
relat
hepat
c
viru
identifi
multipl
compound
inhibitori
activ
zika
proteas
one
peptidomimet
boronicacid
inhibitor
report
proteas
date
nonpeptid
small
molecul
inhibitor
categor
two
differ
scaffold
two
competit
inhibitor
scaffold
provid
good
start
point
develop
low
molecular
weight
inhibitor
potenti
broadspectrum
activ
limit
side
effect
also
determin
crystal
structur
proteas
preopen
conform
conform
never
observ
flaviviru
proteas
conform
activ
site
miss
fundament
structur
featur
enzymat
activ
close
conform
erbel
et
al
robin
et
al
new
find
suggest
sequenc
mechanist
event
dynam
enzym
activ
site
fig
pro
flaviviru
preopen
conform
short
rest
cterminu
stabil
hydrophob
interact
two
c
terminu
disord
state
bind
site
well
develop
enzym
abl
bind
substrat
fig
ii
open
conform
ie
structur
dengu
viru
proteas
pdbcode
form
stabil
interact
pro
state
bind
site
structur
bind
substrat
fig
e
iii
close
conform
bind
substrat
substratelik
molecul
involv
cterminu
reorgan
stabil
cterminu
pro
fig
f
structur
zika
viru
proteas
preopen
conform
provid
new
possibl
design
new
class
antivir
compound
identifi
sever
small
molecul
inhibitor
zika
proteas
two
lead
compound
determin
competit
inhibitor
enzymat
competit
spr
bind
analys
determin
xray
structur
apo
zika
proteas
preopen
conform
